Altamira Therapeutics Ltd (CYTO) News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results

Hamilton, Bermuda, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Company to host conference call today at 8.30 a.m...

Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024

Hamilton, Bermuda, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering

Hamilton, Bermuda, Sept. 19, 2024 (GLOBE NEWSWIRE) -- $4 million upfront with up to an additional $8 million...

Form 424B4 - Prospectus [Rule 424(b)(4)]

Form EFFECT - Notice of Effectiveness

Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering

Hamilton, Bermuda, Sept. 17, 2024 (GLOBE NEWSWIRE) -- $4 million upfront with up to an additional $8 million...

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]

Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia

Hamilton, Bermuda, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Nuance Pharma successfully launched Bentrio® nasal...

Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11

Hamilton, Bermuda, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the...

Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark

Hamilton, Bermuda, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Successful launch of Bentrio by Pharma Nordic AS in...